安罗替尼联合IP方案治疗进展/复发小细胞肺癌临床研究OACSTPCD

Objective To investigate the clinical efficacy and mechanism of anlotinib combined with IP regimen(irinotecan + cisplatin)in the treatment of progressive/recurrent small cell lung cancer(SCLC).Methods A total of 97 patients with progressive/recurrent SCLC admitted to the hospital from June 2019 to June 2021 were selected and divided into the control group(48 cases)and the observation group(49 cases)by the random number table method.The patients in the two groups were treated with IP regimen,on this basis,the patients in the observation group were treated with Anlotinib Hydrochloride Capsules orally.Both groups were treated continuously for two cycles with 28 d as one cycle and followed up for 20 months.Results The disease control rate(DCR)in the observation group was significantly higher than that in the control group(P<0.05).After treatment,the serum carcinoembryonic antigen(CEA),neuron-specific enolase(NSE)and cytokeratin 19 fragment(Cyfra21-1)levels,metabolic tumor volume(MTV),blood volume(BV)and blood flow(BF)in the observation group were significantly lower than those in the control group(P<0.05).The median progression-free survival(PFS)in the observation group was significantly longer than that in the control group(7.5 months vs.5.5 months,P<0.05).There was no significant difference in the incidence of adverse reactions of different levels and survival rate between the two groups(P>0.05).Conclusion Anlotinib combined with IP regimen in the treatment of progressive/recurrent SCLC can reduce the tumor burden and prolong the PFS of patients.The mechanism may be related to the regulation of tumor markers and improvment of blood perfusion-related indexes.